Karin Holmskov Hansen

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2017 · 583 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier et al. · Journal of Thoracic Oncology · 2021 · 258 citations · Full text

Medicine, Oncology, Pharmacology +16

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Rudolf M. Huber, Karin Holmskov Hansen, Luis Paz-Ares Rodríguez et al. · Journal of Thoracic Oncology · 2019 · 144 citations · Full text

Medicine, Oncology, Pharmacology +14

The occurrence of hyponatremia in SCLC and the influence on prognosis

Olfred Hansen, Peter L. Sørensen, Karin Holmskov Hansen · Lung Cancer · 2009 · 139 citations

Medicine, Nephrology, Oncology +2

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)

Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman et al. · Lung Cancer · 2020 · 70 citations · Full text

Medicine, Oncology, Pharmacology +14